IMU (ASX) Media Thread

Originally posted by Jov88: ↑

In London so bit behind, but have read all comments and watched the video. Couldn't have asked for more based on cohorts. Suffice it to say, CF33 works! Would have liked to see the imaging especially on intravenous, based on Leslies comments, higher doses might be the ticket to see desired effecacy. Ultimately, we know IT works very well because the the virus is able to replicate faster than the injected tumour and keep doing so until it bursts and pours out a high amount of virus to go and destroy other tumours. It's a non linear situation we are likely to experience, I think they why it's so important to continue getting data. If the patients immunity is shot, less of a response but less CF33 cleared so more replication but less immune response, also the lymphatic system is also unique in terms of spread depending on cancer so how far the virus needs to travel to get to metastisasis isn't constant.

I am very happy overall, and explains why IMU have bought Azer Cell, they are confident CF33 work-s! Still not certain of TCell exhaustion which is an issue with many CAR Ts but a lot of new data is out of how to curb that. Ultimately, IMU has a therapy that can find and infultrate cancer. We know this because the patient with a complete response had malignant tumours but were injected direct into tumours. We know it kills tumours also, givrnthe complete response. We also know (and this is a big one) safety is high and toxicity is low so little patient burden, what a relief for those patients! OnCARlytics is looking amazing right now…

Also, I bumped this post to show some of the comparative data for therapies that are getting bought out for billions. Keep in mind which data is for solid tumours and which for blood and you'll see what's highly sort after even with horrible sides…we are looking good, just a matter of time.

Cheers.

Ps: thanks for every ones analysis, super helpful.

Expand

Re T Cell exhaustion strategy:

Clinical Oncology Journal Author Oncologist Steven Albelda :"An alternative strategy focused on administering multiple doses of short-lived CAR T cells in an attempt to pre-empt exhaustion and maintain a functional effector pool".
Originally posted by Jov88

Originally posted by Jov88: ↑

In London so bit behind, but have read all comments and watched the video. Couldn't have asked for more based on cohorts. Suffice it to say, CF33 works! Would have liked to see the imaging especially on intravenous, based on Leslies comments, higher doses might be the ticket to see desired effecacy. Ultimately, we know IT works very well because the the virus is able to replicate faster than the injected tumour and keep doing so until it bursts and pours out a high amount of virus to go and destroy other tumours. It's a non linear situation we are likely to experience, I think they why it's so important to continue getting data. If the patients immunity is shot, less of a response but less CF33 cleared so more replication but less immune response, also the lymphatic system is also unique in terms of spread depending on cancer so how far the virus needs to travel to get to metastisasis isn't constant.

I am very happy overall, and explains why IMU have bought Azer Cell, they are confident CF33 work-s! Still not certain of TCell exhaustion which is an issue with many CAR Ts but a lot of new data is out of how to curb that. Ultimately, IMU has a therapy that can find and infultrate cancer. We know this because the patient with a complete response had malignant tumours but were injected direct into tumours. We know it kills tumours also, givrnthe complete response. We also know (and this is a big one) safety is high and toxicity is low so little patient burden, what a relief for those patients! OnCARlytics is looking amazing right now…

Also, I bumped this post to show some of the comparative data for therapies that are getting bought out for billions. Keep in mind which data is for solid tumours and which for blood and you'll see what's highly sort after even with horrible sides…we are looking good, just a matter of time.

Cheers.

Ps: thanks for every ones analysis, super helpful.

Expand

No.	Vol.	Price($)
32	3582759	4.8¢

No.

Vol.

Price($)

3582759

4.8¢

Price($)	Vol.	No.
4.9¢	5042232	17

Price($)

Vol.

No.

4.9¢

5042232

No.	Vol.	Price($)
30	3468852	0.048
38	2105422	0.047
62	5454232	0.046
58	6610473	0.045
17	3232514	0.044

No.

Vol.

Price($)

3468852

0.048

2105422

0.047

5454232

0.046

6610473

0.045

3232514

0.044

Price($)	Vol.	No.
0.049	5075289	17
0.050	3741630	24
0.051	7235912	17
0.052	1620378	11
0.053	809770	10

Price($)

Vol.

No.

0.049

5075289

0.050

3741630

0.051

7235912

0.052

1620378

0.053

809770

(20min delay)
Last 4.9¢		Change 0.001(2.08%)		Mkt cap ! $364.4M

Open	High	Low	Value	Volume
4.8¢	4.9¢	4.8¢	$239.6K	4.948M

Media Thread, page-10529

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Alchemy signs farm-in agreement with Japanese government for development of WA's Karonie

Vinyl expands into UK and European markets with acquisition of Serenade platform

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Media Thread, page-10529

Top Stories

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Alchemy signs farm-in agreement with Japanese government for development of WA's Karonie

Vinyl expands into UK and European markets with acquisition of Serenade platform

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News